Sarasota Memorial Hospital
Sarasota, Florida 34329
28 studies enrolling now · 154 studies all time
What they study most
ADH Inappropriate, ARDS, ARDS (Acute Respiratory Distress Syndrome), Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder), Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysms, Ablation, Acute Ischemic Stroke, Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome (ARDS)
Studies at this site
- A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer — Recruiting now
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma — Recruiting now
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 — Recruiting now
- Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure — Recruiting now
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart — Recruiting now
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab — Recruiting now
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab — Recruiting now
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) — Recruiting now
- Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma — Recruiting now
- DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis — Recruiting now
- Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER — Recruiting now
- Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula — Recruiting now
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT — Recruiting now
- Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias — Recruiting now
- The PERSEVERE Study — Recruiting now
- Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial — Recruiting now
- Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study — Recruiting now
- BoxX-NoAF Clinical Trial — Recruiting now
- Inappropriate Sinus Tachycardia Registry — Recruiting now
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — Recruiting now
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke — Recruiting now
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma — Recruiting now
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) — Recruiting now
- De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) — Recruiting now
- Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System — Recruiting now
- The ENCIRCLE Trial — Recruiting now
- A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease — Recruiting now
- SIMPLAAFY Clinical Trial — Running, not enrolling
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Running, not enrolling
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer — Running, not enrolling
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Running, not enrolling
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — Completed
- Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer — Paused
- NCI COVID-19 in Cancer Patients, NCCAPS Study — Running, not enrolling
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — Running, not enrolling
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
- Xeltis Hemodialysis Access Graft (aXess) US Study — Enrolling by invitation
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation — Running, not enrolling
- Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers — Running, not enrolling
- A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF — Enrolling by invitation
- BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S — Completed
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Running, not enrolling
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
- A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination — Paused
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone — Running, not enrolling
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer — Running, not enrolling
- Florida Pancreas Collaborative Next Generation Biobank — Running, not enrolling
- SPHERE Per-AF Post-Approval Study — Running, not enrolling
- Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer — Running, not enrolling
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer — Running, not enrolling